In prostate cancer patients, initially managed with curative intent, in whom BCR is observed, the proper determination of the sites of disease relapse, especially differentiation between local recurrence, nodal involvement, or distant dissemination, appears to be essential. The gene discussed is BCR; the disease is Familial prostate cancer.